Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Bio-ADAURA: Neoadjuvant Osimertinib in EGFRm NSCLC
NCT06206850Phase 2Recruiting
- Start
- Feb 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC). Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06206850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206850.